Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Launch of Cetaphil Restoraderm.
Plant extensions in France and Canada.
Differin Lotion 0.1% (acne) launch in the United States.
Galderma hits the 1 billion mark in sales.
Launch of Azzalure (glabellar lines) and Oracea in Europe.
Vectical (psoriasis) launch in the United-States. Oracea
||Epiduo (acne) launch.
Acquisition of CollaGenex Pharmaceuticals and its product Oracea (rosacea).
Launch of Differin 0.1% in Japan. Differin
||Licensing agreements for a botulinum toxin type A and Pliaglis (topical anesthetic).
Differin 0.3% launch. Pliaglis
||Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France.
||Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).
||Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.
||Launch of Metvix in Germany and the UK and Clobex Lotion (inflammatory skin conditions) in the US.
||Licensing agreements for Tri-Luma (melasma or mask of pregnancy) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.
||Licensing agreement for Metvix (precancerous skin lesions and skin cancer treatment).
Launch of Clindagel (anti-acne).
||The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).
||Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.
||Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.
||Acquisition of Basotherm, a subsidiary of Boehringer.
||Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
||Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.
||Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.
||Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.
||Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.
||Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.
||Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.
||Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.
||L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.
||Nestlé acquires Alcon to strengthen its presence in the North American market.
||Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.
Creation of the Owen dermatology company in Dallas, Texas, USA.